Literature DB >> 29172909

Health Care Utilization Following Vagus Nerve Stimulation Therapy in Pediatric Epilepsy Patients From a Pediatric Accountable Care Organization.

Anup Patel1,2, Ling Wang3, Satyanarayana Gedela1,2.   

Abstract

BACKGROUND: Vagus nerve stimulation has been a therapy for epilepsy approved by the US Food and Drug Administration (FDA) for patients 4 and older and shown efficacy and safety in younger pediatric patients.
METHODS: The authors performed a retrospective analysis utilizing Medicaid claims from an accountable care organization to measure the intervention of vagus nerve stimulation therapy in regard to unplanned health care utilization. Thirteen unique patients were included who had vagus nerve stimulation therapy who had at least 6 months of continuous enrollment in a managed Medicaid health plan. Comparison with 12 months of data before and after vagus nerve stimulation implantation was performed.
RESULTS: Patients had statistically significant fewer unplanned inpatient visits per patient per enrollment month after vagus nerve stimulation implantation.
CONCLUSION: Utilizing claims data, vagus nerve stimulation implantation demonstrates a reduction in unplanned hospitalizations.

Entities:  

Keywords:  health care utilization; hospitalizations; vagus nerve stimulation

Mesh:

Year:  2017        PMID: 29172909     DOI: 10.1177/0883073817743639

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  1 in total

1.  Hospital costs associated with vagus nerve stimulation and medical treatment in pediatric patients with refractory epilepsy.

Authors:  Lu Zhang; Matt Hall; Sandi K Lam
Journal:  Epilepsia       Date:  2022-03-13       Impact factor: 6.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.